IRMD Iradimed Corp

IRADIMED CORPORATION to Hold 2020 Third Quarter Financial Results Conference Call on October 30th

IRADIMED CORPORATION to Hold 2020 Third Quarter Financial Results Conference Call on October 30th
EN
08/10/2020

Underlying

IRMDIradimed Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iradimed Corp

Free Trial
IRMD IRADIMED CORP

Iradimed Corp: 1 director

A director at Iradimed Corp sold 7,500 shares at 95.015USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

17h / 15m 17h / 15m 1 EN
 PRESS RELEASE
Free
IRMD IRADIMED CORP

IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference

IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38th Annual Roth Conference. Iradimed’s CEO, Roger Susi, and CFO, Jack Glenn, will host one-on-one meetings between company management and investors at the 38th Annual Roth Conference, which will be held at the Ritz-Carlton in Laguna Niguel, CA, on March 22 and 24, 2026. About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“M...

March 16, 2026 1 EN
 PRESS RELEASE
Free
IRMD IRADIMED CORP

IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 20...

IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0.54 for the fourth quarter of 2025, which are increases of 25% and 23%, respectively, compared to the same period in 2024. Reports record GAAP diluted EPS of $1.75 and non-GAAP diluted EPS of $1.93...

February 10, 2026 1 EN
 PRESS RELEASE
Free
IRMD IRADIMED CORP

IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financi...

IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026 ORLANDO, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 fourth quarter and full year financial results before the market opens on Tuesday, February 10, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registerin...

February 4, 2026 1 EN
 PRESS RELEASE
Free
IRMD IRADIMED CORP

IRADIMED Announces Special Cash Dividend of $0.50 Per Share

IRADIMED Announces Special Cash Dividend of $0.50 Per Share ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company produces the onl...

December 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch